Literature DB >> 32203258

Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML.

Will P Bultitude1,2, Jennifer Schellekens1,2, Richard M Szydlo1,3, Chloe Anthias1,4, Sarah A Cooley5, Jeffrey S Miller6, Daniel J Weisdorf6, Bronwen E Shaw7, Chrissy H Roberts8, Christian A Garcia-Sepulveda9, Julia Lee10, Rachel M Pearce10, Marie C Wilson1,10, Michael N Potter4, Jenny L Byrne11, Nigel H Russell11, Stephen MacKinnon12, Adrian J Bloor13, Amit Patel14, I Grant McQuaker15, Ram Malladi16, Eleni Tholouli17, Kim Orchard18, Victoria T Potter19, J Alejandro Madrigal1,2, Neema P Mayor1,2, Steven G E Marsh20,21.   

Abstract

The reported influence of donor Killer-cell Immunoglobulin-like Receptor (KIR) genes on the outcomes of haematopoietic cell transplantation (HCT) are contradictory, in part due to diversity of disease, donor sources, era and conditioning regimens within and between different studies. Here, we describe the results of a retrospective clinical analysis establishing the effect of donor KIR motifs on the outcomes of 119 HLA-matched, unrelated donor HCT for adult acute myeloid leukaemia (AML) using myeloablative conditioning (MAC) in a predominantly T-cell deplete (TCD) cohort. We observed that HCT involving donors with at least one KIR B haplotype were more likely to result in non-relapse mortality (NRM) than HCT involving donors with two KIR A haplotypes (p = 0.019). Upon separation of KIR haplotypes into their centromeric (Cen) and telomeric (Tel) motif structures, we demonstrated that the Cen-B motif was largely responsible for this effect (p = 0.001). When the cause of NRM was investigated further, infection was the dominant cause of death (p = 0.006). No evidence correlating donor KIR B haplotype with relapse risk was observed. The results from this analysis confirm previous findings in the unrelated, TCD, MAC transplant setting and imply a protective role for donor-encoded Cen-A motifs against infection in allogeneic HCT recipients.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32203258      PMCID: PMC8852820          DOI: 10.1038/s41409-020-0858-9

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  23 in total

1.  Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality.

Authors:  Antonella Mancusi; Loredana Ruggeri; Elena Urbani; Antonio Pierini; Maria Speranza Massei; Alessandra Carotti; Adelmo Terenzi; Franca Falzetti; Antonella Tosti; Fabiana Topini; Silvia Bozza; Luigina Romani; Rita Tognellini; Martin Stern; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Blood       Date:  2015-03-13       Impact factor: 22.113

2.  Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.

Authors:  Sebastian Giebel; Franco Locatelli; Teresa Lamparelli; Andrea Velardi; Stella Davies; Guido Frumento; Rita Maccario; Federico Bonetti; Jerzy Wojnar; Miryam Martinetti; Francesco Frassoni; Giovanna Giorgiani; Andrea Bacigalupo; Jerzy Holowiecki
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

3.  Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.

Authors:  Nicolaus Kröger; Thomas Binder; Tatjana Zabelina; Christine Wolschke; Heike Schieder; Helmut Renges; Francis Ayuk; Joachim Dahlke; Thomas Eiermann; Axel Zander
Journal:  Transplantation       Date:  2006-10-27       Impact factor: 4.939

4.  HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.

Authors:  Jeffrey M Venstrom; Gianfranco Pittari; Ted A Gooley; Joseph H Chewning; Stephen Spellman; Michael Haagenson; Meighan M Gallagher; Mari Malkki; Effie Petersdorf; Bo Dupont; Katharine C Hsu
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

5.  Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.

Authors:  Sarah Cooley; Daniel J Weisdorf; Lisbeth A Guethlein; John P Klein; Tao Wang; Chap T Le; Steven G E Marsh; Daniel Geraghty; Stephen Spellman; Michael D Haagenson; Martha Ladner; Elizabeth Trachtenberg; Peter Parham; Jeffrey S Miller
Journal:  Blood       Date:  2010-06-25       Impact factor: 22.113

6.  Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.

Authors:  Nicolaus Kröger; Bronwen Shaw; Simona Iacobelli; Tatjana Zabelina; Karl Peggs; Avichai Shimoni; Arnon Nagler; Thomas Binder; Thomas Eiermann; Alejandro Madrigal; Rainer Schwerdtfeger; Michael Kiehl; Herbert Gottfried Sayer; Jörg Beyer; Martin Bornhäuser; Francis Ayuk; Axel Rolf Zander; David I Marks
Journal:  Br J Haematol       Date:  2005-06       Impact factor: 6.998

7.  Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.

Authors:  Loredana Ruggeri; Marusca Capanni; Elena Urbani; Katia Perruccio; Warren D Shlomchik; Antonella Tosti; Sabrina Posati; Daniela Rogaia; Francesco Frassoni; Franco Aversa; Massimo F Martelli; Andrea Velardi
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

8.  High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation.

Authors:  Stephanie J Lee; John Klein; Michael Haagenson; Lee Ann Baxter-Lowe; Dennis L Confer; Mary Eapen; Marcelo Fernandez-Vina; Neal Flomenberg; Mary Horowitz; Carolyn K Hurley; Harriet Noreen; Machteld Oudshoorn; Effie Petersdorf; Michelle Setterholm; Stephen Spellman; Daniel Weisdorf; Thomas M Williams; Claudio Anasetti
Journal:  Blood       Date:  2007-09-04       Impact factor: 22.113

9.  The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy.

Authors:  Craig Kollman; Stephen R Spellman; Mei-Jie Zhang; Anna Hassebroek; Claudio Anasetti; Joseph H Antin; Richard E Champlin; Dennis L Confer; John F DiPersio; Marcelo Fernandez-Viña; Robert J Hartzman; Mary M Horowitz; Carolyn K Hurley; Chatchada Karanes; Martin Maiers; Carlheinz R Mueller; Miguel-Angel Perales; Michelle Setterholm; Ann E Woolfrey; Neng Yu; Mary Eapen
Journal:  Blood       Date:  2015-11-02       Impact factor: 22.113

10.  Estimating KIR Haplotype Frequencies on a Cohort of 10,000 Individuals: A Comprehensive Study on Population Variations, Typing Resolutions, and Reference Haplotypes.

Authors:  Cynthia Vierra-Green; David Roe; Jyothi Jayaraman; John Trowsdale; James Traherne; Rui Kuang; Stephen Spellman; Martin Maiers
Journal:  PLoS One       Date:  2016-10-10       Impact factor: 3.240

View more
  3 in total

1.  Donor Killer Immunoglobulin Receptor Gene Content and Ligand Matching and Outcomes of Pediatric Patients with Juvenile Myelomonocytic Leukemia Following Unrelated Donor Transplantation.

Authors:  Hemalatha G Rangarajan; Marcelo S F Pereira; Ruta Brazauskas; Andrew St Martin; Ashleigh Kussman; Ezgi Elmas; Michael R Verneris; Shahinaz M Gadalla; Steven G E Marsh; Sophie Paczesny; Stephen R Spellman; Stephanie J Lee; Dean A Lee
Journal:  Transplant Cell Ther       Date:  2021-08-15

2.  Following Transplantation for Acute Myelogenous Leukemia, Donor KIR Cen B02 Better Protects against Relapse than KIR Cen B01.

Authors:  Lisbeth A Guethlein; Niassan Beyzaie; Neda Nemat-Gorgani; Tao Wang; Vidhyalakshmi Ramesh; Wesley M Marin; Jill A Hollenbach; Johannes Schetelig; Stephen R Spellman; Steven G E Marsh; Sarah Cooley; Daniel J Weisdorf; Paul J Norman; Jeffrey S Miller; Peter Parham
Journal:  J Immunol       Date:  2021-06-11       Impact factor: 5.426

Review 3.  Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation.

Authors:  Fei Gao; Yishan Ye; Yang Gao; He Huang; Yanmin Zhao
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.